Abstract
Background
The IABP-SHOCK-trial was a morbidity-based randomized controlled trial in patients with infarction-related cardiogenic shock (CS), which used the change of the quantified degree of multiorgan failure as determined by APACHE II score over a 4-day period as primary outcome measure. The prospective hypothesis was that adding IABP therapy to “standard care” would improve CS-triggered multi organ dysfunction syndrome (MODS). The primary endpoint showed no difference between conventionally managed cardiogenic shock patients and those with IABP support. In an inflammatory marker substudy, we analysed the prognostic value of interleukin (IL)-1β, -6, -7, -8, and -10 in patients with acute myocardial infarction complicated by cardiogenic shock.
Design
Inflammatory marker substudy of the prospective, randomized, controlled, open label IABP-SHOCK-trial (Clinical-Trials-gov-ID-NCT00469248).
Setting and methods
A single-center study was performed in a 12-bed Intensive-Care-Unit in an university hospital in which 40 consecutive patients were enrolled with an observational period of 96 h.
Results
The pro- and anti-inflammatory markers IL-6, -7, -8 and -10 showed a predictive power for mortality of infarct-related CS patients, while IL-1β did not discriminate. The maximal values during the observational period, in case of IL-7 the minimal value, showed the best power to predict mortality. Both, ROC and multivariate analyses confirmed these suggestions (area under the curve: IL-8, 0.80 ± 0.08; IL-6, 0.79 ± 0.08; IL-10, 0.76 ± 0.08; IL-7, 0.69 ± 0.08). Inflammatory markers were not affected by the presence of IABP support.
Conclusion
The inflammatory response in patients with myocardial infarction complicated by cardiogenic shock, as reflected by the inflammatory markers IL-6, IL-7, IL-8 and IL-10, demonstrates a clinically relevant prognostic contribution to clinical outcome.
Similar content being viewed by others
References
Prondzinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM, Russ M, Schlitt A, Buerke U, Christoph A, Schmidt H, Winkler M, Thiery J, Werdan K, Buerke M (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38:152–160
Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341:625–634
Ruiz-Bailen M, Rucabado-Aguilar L, Exposito-Ruiz M et al (2009) Cardiogenic shock in acute coronary syndrome. Med Sci Monit 15:RA57–RA66
Kouraki K, Schneider S, Uebis R, Tebbe U, Klein HH, Janssens U, Zahn R, Senges J, Zeymer U (2011) Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group. Clin Res Cardiol 100(3):235–239
Liebetrau C, Szardien S, Rixe J, Woelken M, Rolf A, Bauer T, Nef H, Möllmann H, Hamm C, Weber M (2011) Direct admission versus transfer of AMI patients for primary PCI. Clin Res Cardiol 100(3):217–225
Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA, Mohanavelu S, Rouleau J, Fox K, Pedersen TR, Califf RM (2009) Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. Clin J Am Soc Nephrol 4:1811–1817
Tan J, Hua Q, Li J, Fan Z (2009) Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessels 24:329–334
Järemo P, Nilsson O (2008) Interleukin-6 and neutrophils are associated with long-term survival after acute myocardial infarction. Eur J Intern Med 19:330–333
Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R, Bertel O, Frielingsdorf J (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298–305
Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, Siostrzonek P, Huber K, Heinz G (2002) Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 30:1987–1994
Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS (2005) SHOCK Investigators. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165:1643–1650
Lin WC, Lin CF, Chen CL, Chen CW, Lin YS (2010) Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. Exp Biol Med 235:57–65
Prinsen JH, Baranski E, Posch H, Tober K, Gerstmeyer A (2008) Interleukin-6 as diagnostic marker for neonatal sepsis: determination of Access IL-6 cutoff for newborns. Clin Lab 54:179–183
Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R, Speichermann N, Verner L, Werdan K (2003) Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 29:1696–1702
Altman DA (1991) Practical statistics for medical research. Chapman & Hall, London
Sauerbrei W, Madjar H, Prömpeler HJ (1998) Differentiation of benign and malignant breast tumours by logistic regression and a classification tree using Doppler flow signals. Methods Inf Med 37:226–234
Känel R, Carney RM, Zhao S, Whooley MA (2011) Heart rate variability and biomarkers of systemic inflammation in patients with stable coronary heart disease: findings from the Heart and Soul Study. Clin Res Cardiol 100(3):241–247
Villar J, Maca-Meyer N, Pérez-Méndez L, Flores C (2004) Bench-to-bedside review: understanding genetic predisposition to sepsis. Crit Care 8:180–189
Fitting C, Cheval C, Losser MR, Carlet J, Payen D, Foster K, Cavaillon JM (1997) Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome. Infect Immun 65:865–871
Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE, Wuillemin WA (2003) Clin Diagn Lab Immunol 10:529–535
Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, Moutardier V, Blache JL (2005) Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 94:767–773
Weber GF, Schlautkötter S, Kaiser-Moore S, Altmayr F, Holzmann B, Weighardt H (2007) Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect Immun 75:1690–1697
Torre-Amnione Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704–711
Werra ID (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factro receptors, and procalcitonin concentrations: comparison in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25:607–613
Neumann FJ, Ott I, Gawaz M et al (1995) Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 92:748–755
Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C, Fraisse F, Dinh-Xuan AT, Carli P, Spaulding C, Dhainaut JF, Cavaillon JM (2002) Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106:562–568
Kohsaka S, Menon V, Iwata K, Lowe A, Sleeper LA, Hochman JS (2007) SHOCK investigators. Microbiological profile of septic complication in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK study). Am J Cardiol 99:802–804
Kadokami T, McTiernan C, Kubota T, Frye C, Bounoutas G, Robbins P, Watkins S, Feldman A (2001) Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 280:H2281–H2291
Miettinen JA, Ylitalo K, Hedberg P, Kervinen K, Niemelä M, Säily M, Koistinen P, Savolainen ER, Ukkonen H, Pietilä M, Airaksinen KE, Knuuti J, Vuolteenaho O, Mäkikallio TH, Huikuri HV (2011) Effects of intracoronary injection of autologous bone marrow-derived stem cells on natriuretic peptides and inflammatory markers in patients with acute ST-elevation myocardial infarction. Clin Res Cardiol 100(4):317–325
Prondzinsky R, Müller-Werdan U, Pilz G, Witthaut R, Stabenow I, Werdan K, Zerkowski HR (1997) Systemic inflammatory reactions to extracorporeal therapy measures (II): cardiopulmonary bypass. Wien Klin Wochenschr 109:346–353
Prondzinsky R, Knüpfer A, Loppnow H, Redling F, Lehmann DW, Stabenow I, Witthaut R, Unverzagt S, Radke J, Zerkowski HR, Werdan K (2005) Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 129:760–766
Kilger E, Heyn J, Beiras-Fernandez A, Luchting B, Weis F (2011) Stress doses of hydrocortisone reduce systemic inflammatory response in patients undergoing cardiac surgery without cardiopulmonary bypass. Minerva Anestesiol 77:268–274
Steinvil A, Berliner S, Shapira I, Rogowski O, Justo D, George J, Halkin A, Keren G, Finkelstein A, Banai S, Arbel Y (2010) Time to rheology in acute myocardial infarction: inflammation and erythrocyte aggregation as a consequence and not necessarily as precursors of the disease. Clin Res Cardiol 99(10):651–656
Jung C, Rödiger C, Fritzenwanger M, Schumm J, Lauten A, Figulla HR, Ferrari M (2009) Acute microflow changes after stop and restart of intra-aortic balloon pump in cardiogenic shock. Clin Res Cardiol 98(8):469–475
Munsterman LD, Elbers PW, Ozdemir A, van Dongen EP, van Iterson M, Ince C (2010) Withdrawing intra-aortic balloon pump support paradoxically improves microvascular flow. Crit Care 14(4):R161
Osuchowski MF, Welch K, Siddiqui J, Remick DG (2006) Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177:1967–1974
Schröder J, Kahlke V, Staubach KH, Zabel P, Stüber F (1998) Gender differences in human sepsis. Arch Surg 133:1200–1205
Arranz L, Lord JM, De la Fuente M (2010) Preserved ex vivo inflammatory status and cytokine responses in naturally long-lived mice. Age (Dordr) 32:451–466
Agarwal S, Busse PJ (2010) Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol 104:183–190
Wong CP, Magnusson KR, Ho E (2010) Aging is associated with altered dendritic cells subset distribution and impaired proinflammatory cytokine production. Exp Gerontol 45:163–169
Schmidt C, Höcherl K, Kurt B, Moritz S, Kurtz A, Bucher M (2010) Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock. Cytokine 49:30–38
Cha J, Wang Z, Ao L et al (2008) Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg 85:1678–1685
Katz JN, Stebbins AL, Alexander JH, Reynolds HR, Pieper KS, Ruzyllo W, Werdan K, Geppert A, Dzavik V, Van de Werf F, Hochman JS (2009) TRIUMPH investigators. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery. Am Heart J 158:680–687
Youssef AA, Chang LT, Hang CL, Wu CJ, Cheng CI, Yang CH, Sheu JJ, Chai HT, Chua S, Yeh KH, Yip HK (2007) Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 71:703–708
Yamamoto T, Terajima K, Kato K, Iwasaki YK, Miyagi Y, Sato N, Takeda S, Tanaka K, Takano T (2006) Transient leukocytopenia associated with a steep surge of pro-inflammatory cytokines in a patient with severe cardiogenic pulmonary edema. Intern Med 45:1153–1155
Buerke M, Murohara T, Skurk C et al (1995) Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci 92:8031–8035
Rupprecht HJ, vom Dahl J, Terres W et al (2000) Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101:2902–2908
Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693–2701
Conflict of interest
The authors declare the following relations: R.P., K.W., and M.B. received lecture fees from Datascope Inc. The IABP-Shock-Trial was supported by an unrestricted grant from Datascope Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prondzinsky, R., Unverzagt, S., Lemm, H. et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol 101, 375–384 (2012). https://doi.org/10.1007/s00392-011-0403-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-011-0403-3